Next 10 |
home / stock / pbla / pbla articles
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares are trading lower over 2% on Tuesday, ending Monday’s session with a whopping 65.3%...
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. The Dow traded up ...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday. The Dow traded down 0.04% to 38,093....
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 25 points on Monday. Following the market opening Monday, ...
ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares rose sharply in today's pre-market trading after Jefferies upgraded the stock from Hol...
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but is...
Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares are trading higher on very heavy volume Friday. Here’s a look at what’s going on. What...
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This ind...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 ...